[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"weight-management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:weight-management":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,43,68,90,117,150,180,216,246,267,299,346,375,407,431,451],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100554983","phase-1-a-clinical-study-to-evaluate-the-effect-of-different-dosing-conditions-on-the-pharmacokinetics-of-hrs9531-tablets-in-healthy-participants-100554983",false,"NCT06506175","A Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants","A Phase I Clinical Study to Evaluate the Effect of Different Dosing Conditions on the Pharmacokinetics of HRS9531 Tablets in Healthy Participants","Inclusion Criteria:\n\n1. Ability to understand the trial procedures, be able and willing to provide a written informed consent.\n2. Male subject aged 18-55 years (both inclusive) at the time of signing informed consent.\n3. Body weight ≥ 50.0 kg, body mass index (BMI) of 23.0-35.0 kg\u002Fm\\^2 (both inclusive) at screening.\n4. Weight change does not exceed 5 kg within 3 months before screening.\n5. Good general health as judged by the investigator, based on medical history, physical examination, vital signs, clinical laboratory and electrocardiogram (ECG).\n\nExclusion Criteria:\n\n1. Known or suspected hypersensitivity to trial product(s) or related products.\n2. With previous major organ diseases, including but not limited to neuropsychiatric, cardiovascular, digestive, respiratory, urinary, endocrine, blood, immune and other diseases, are judged by researchers to be unsuitable for the study.\n3. Abnormal and clinically significant blood pressure at screening.\n4. History of significant gastrointestinal diseases or related symptoms (e.g., nausea, vomiting, heartburn, or diarrhea), conditions affecting gastric emptying (e.g., pyloric stenosis), or previous gastrointestinal surgery (excluding polypectomy and appendectomy), or acute diarrhea or constipation within 7 days before randomization.\n5. Blood donation within 1 month prior to screening, or blood donation ≥ 400 mL or blood loss ≥ 400 mL within 3 months prior to screening.\n6. Presence of any clinically significant results in examination at screening visit.\n7. Hepatitis B surface antigen (HBsAg), HIV antibody detection, treponema pallidum specific antibody detection, hepatitis C virus antibody (HCVAb) positive.\n8. Presence of - clinically significant ECG results.\n9. Known or suspected history of drug abuse or drug abuse, or urine drug screening test during the screening periodThose who are positive.\n10. Addiction to tobacco and alcohol.\n11. Individuals with special dietary habits deemed unsuitable for participation by the investigator, or those unable to adhere to the dietary requirements of the trial during the study period.\n12. In the opinion of the investigator, there are any other conditions that interfere with the evaluation of the results of the trial or are not suitable for participation of this study.",true,"MALE","18 Years","55 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","The study is being conducted to evaluate the effects of different dosage regimen on the pharmacokinetics of HRS9531 tablets in healthy subjects.",[28,29],"Weight Management","Type 2 Diabetes","NOT_YET_RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-24","ACTUAL",{"date":36,"type":22},"2026-07",{"date":38,"type":22},"2026-09",{"name":40,"class":41},"Fujian Shengdi Pharmaceutical Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":67},"100643849","phase-3-a-master-protocol-to-investigate-efficacy-and-safety-of-elecoglipron-in-participants-with-obesity-or-overweight-with-or-without-t2dm-100643849","NCT07667803","A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM","A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without Type 2 Diabetes Mellitus (Embold)","Embold","Inclusion Criteria\n\n* Legal age of consent and at least 18 years old\n* Study 1 -\n\n  * BMI ≥ 30 kg\u002Fm2 or\n  * 25 kg\u002Fm2 ≤ BMI \\\u003C 30 kg\u002Fm2 with at least one of the following weight-related comorbidities:\n  * Hypertension\n  * Prediabetes\n  * Dyslipidemia\n  * Cardiovascular disease\n  * Obstructive sleep apnea.\n* Study 2 - BMI ≥ 25 kg\u002Fm2 and T2DM defined as below:\n\n  * Established diagnosis of T2DM\n  * Without established diagnosis of T2DM and HbA1c ≥ 6.5% (48 mmol\u002Fmol) at the screening visit\n* Stable body weight (self-reported or documented) for 90 days prior to the screening visit (± 5% body weight change)\n* History of at least one self-reported unsuccessful dietary effort to lose body weight.\n\nExclusion Criteria\n\n* Study 1 - Established diagnosis of T1DM or T2DM.\n* Study 2 - Any of the following medical history, laboratory values, or complications related to diabetes:\n\n  * T1DM\n  * HbA1c ≥ 10% (86 mmol\u002Fmol) at the screening visit\n  * Currently receiving, or anticipated to receive, therapeutic intervention for diabetic retinopathy and\u002For macular edema.\n  * Have had more than one episode of severe hypoglycemia within 180 days prior to the screening visit, or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms\n* History of acute (unless due to previously resolved gallstone pancreatitis and post-cholecystectomy) or chronic pancreatitis\n* History\u002Ffamily history (first degree biologic relatives) of medullary thyroid cancer or multiple endocrine neoplasia type 2","ALL",{"count":53,"type":22},4500,[55],"PHASE3","This master study protocol, Study D7260C00015, covers 2 independent, pivotal studies, Study 1 and Study 2. Each study is a global, randomized, double-blind, parallel-group, multicenter, Phase III study to assess the efficacy and safety of elecoglipron compared with placebo adjunct to diet and exercise for weight management, in adults living with obesity or overweight with at least one weight-related comorbidity, and without T2DM (Study 1) or with T2DM (Study 2).",[28],"2026-06-19",{"date":60,"type":34},"2026-06-25",{"date":62,"type":22},"2026-07-06",{"date":64,"type":22},"2029-07-30",{"name":66,"class":41},"AstraZeneca",132,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":16,"sex":51,"minAge":18,"maxAge":19,"enrollmentInfo":75,"targetDuration":4,"studyType":23,"phases":77,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100559344","phase-1-study-of-gs-4571-in-healthy-participants-nondiabetic-obese-participants-and-nonobese-participants-with-type-2-diabetes-mellitus-t2dm-100559344","NCT06562907","Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)","A Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Oral Doses of GS-4571 in Healthy Participants, Multiple Ascending Oral Doses of GS-4571 in Nondiabetic Obese Participants and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM), and to Evaluate the Effect of Food and an Acid-Reducing Agent on Pharmacokinetics of GS-4571","Key Inclusion Criteria:\n\n* Individuals must be glucagon-like peptide-1 receptor agonist (GLP-1RA) naïve OR last dose was at least 6 months prior to screening.\n* Part A (SAD) and Part B (Food\u002FPPI Effect): eligible individuals in Cohorts 1-4, (optional cohort 5) and 6 will include healthy individuals with BMI of ≥ 19 and \\\u003C 30 kg\u002Fm\\^2, and no significant medical history.\n\nIndividuals will also be in good general health as determined by the investigator at the screening evaluation performed no more than 28 days prior to the scheduled first dose.\n\n* Part C (MAD in nondiabetic obese individuals): Eligible individuals in Cohorts 7-9 and (optional cohort 10) will be individuals with obesity with BMI ≥ 30 kg\u002Fm\\^2 and \\\u003C 45 kg\u002Fm\\^2 with a total body weight \\> 50 kg, and nondiabetic (HbA1c \\\u003C 6.5%). Eligible individuals will also be individuals with stable body weight (\\\u003C 5% change) for 90 days prior to screening visit based on individual report.\n* Part D (multiple doses in non-obese T2DM): eligible individuals in Cohort 11 will be individuals with T2DM HbA1c ≥ 7.0% and ≤ 10.5% with BMI of ≥ 19 and \\\u003C 30 kg\u002Fm\\^2 and treated with diet and\u002For exercise, and\u002For metformin monotherapy.\n\nKey Exclusion Criteria:\n\n* Have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with individual treatment, assessment, or compliance with the protocol. This would include acute pancreatitis, or history of pancreatitis, acute gallbladder disease, and renal, cardiac, hematological, hepatic, pulmonary (including chronic asthma), endocrine (including diabetes \\[with the exception of T2DM for individuals included in Part D only\\]), central nervous, gastrointestinal (including an ulcer), vascular, metabolic (thyroid disorders, adrenal disease), immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment.\n* Current symptoms of diabetic retinopathy or examination indicating diabetic retinopathy within one year of screening.\n* Any electrolyte disturbances identified at screening considered to be clinically significant in the opinion of the investigator (eg, hypokalemia, hypocalcemia, or hypomagnesemia).\n* Any condition that could lead to electrolyte disturbances (eg, eating disorder) in the opinion of the investigator.\n* History of syncope, palpitations, or unexplained dizziness.\n* Active, or history of, significant cardiac disease or conduction abnormality\n* History of implanted defibrillator or pacemaker.\n* Have been treated with the following within 6 months prior to screening or is expected to receive these agents during the study: GLP-1RAs, systemic steroids, immunosuppressant therapies, or chemotherapeutic agents (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies).\n* Previously stopped use of GLP-1RAs secondary to severe side effects including nausea, constipation, diarrhea, or emesis.\n\nNote: Other protocol defined Inclusion\u002FExclusion criteria may apply.",{"count":76,"type":22},134,[25],"The goal of this clinical study is to learn more about the study drug, GS-4571, and how safe it is in 3 groups, i) Healthy participants, ii) Healthy non-diabetic obese participants, and iii) Non-obese participants with Type 2 Diabetes Mellitus (T2DM).\n\nThe primary objectives of this study are:\n\n* To characterize the pharmacokinetics (PK) of GS-4571 following single and multiple ascending oral doses of GS-4571.\n* To evaluate the effect of concomitant food intake and (if conducted) a representative acid-reducing agent (proton pump inhibitor (PPI), omeprazole) on the PK of GS-4571.\n* To evaluate the safety and tolerability of single and multiple ascending oral doses of GS-4571.",[28],"RECRUITING","2026-06-18",{"date":31,"type":34},{"date":84,"type":34},"2024-08-28",{"date":86,"type":22},"2026-11",{"name":88,"class":41},"Gilead Sciences",3,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":16,"sex":98,"minAge":99,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":23,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":4},"100639032","ttm-based-intervention-for-weight-management-among-high-school-female-students-100639032","NCT07604649","TTM-Based Intervention for Weight Management Among High School Female Students","Efficacy of the Transtheoretical Model of Change-Based Intervention on Weight Management Behavior Among High School Female Students: A Randomized Controlled Trial","TTM-WMHSFS-RCT","Inclusion Criteria:\n\n* Female high school students\n* Age 15-19 years\n* Overweight or obese according to Body Mass Index (BMI) criteria\n* Enrolled in high school morning classes\n* Willing to participate in the study and provide informed consent\n\nExclusion Criteria:\n\n* Students below high school level (e.g., middle school students)\n* Students with physical disabilities that prevent participation in physical activity\n* Students with chronic medical conditions affecting body weight or study participation","FEMALE","15 Years","19 Years",{"count":102,"type":22},154,[104],"NA","To examine the efficacy of a Transtheoretical Model (TTM)-based intervention in improving weight management behaviors.\n\n1. To identify if the student age, body mass index (BMI) and socioeconomic status can predict WMB.\n2. To investigate the difference in students' WMB between groups of grade, liven arrangement, socioeconomic class, and BMI.",[28],"2026-05-19",{"date":109,"type":34},"2026-05-22",{"date":111,"type":22},"2026-10-10",{"date":113,"type":22},"2027-04-10",{"name":115,"class":116},"University of Baghdad","OTHER",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":16,"sex":51,"minAge":125,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":23,"phases":128,"briefSummary":129,"conditions":130,"keywords":135,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":42},"100596775","advancing-biopsychosocial-care-training-initiative-100596775","NCT07049861","Advancing Biopsychosocial Care Training Initiative","Increasing Access to USPSTF-Recommended Obesity Care for Youth and Adults Who Are Recipients of Medicaid: Evaluation of a Comprehensive Multidisciplinary Obesity Care Training Program in FQHCs","ABC Initiative","Study Eligibility Criteria - Provider Trainees:\n\n* Provider Trainees must be PCPs, BHPs, RDNs, or CHWs who work at participating clinics.\n\n  * PCPs that are eligible to participate as Provider Trainees can be any of the following: Medical Doctors (MD), Doctor of Osteopathic Medicine (DO), Physician Assistants (PA), or Nurse Practitioners (NP). PCPs must see patients in a primary care setting and be capable of referring patients to IBT and MNT. PCPs must have already completed their residency (when applicable).\n  * BHPs that are eligible to participate as Provider Trainees must be at least one of the following categories (listed with typical credentials): Licensed Clinical Social Worker (LCSW), Licensed Professional Counselor (LPC), Licensed Marriage and Family Therapist (LMFT), Psychologist (PhD\u002FPsyD), Psychiatric Nurse Practitioner, Psychiatrist (MD).\n  * RDNs that are eligible to participate as Provider Trainees must be Registered Dietitians\u002FRegistered Dietitian Nutritionists.\n  * CHWs must work as Community Health Workers, or in functionally similar role, within participating clinics\n\nStudy Eligibility - EHR Patients: Benefit-Eligible Patients from Participating Clinics\n\n* Benefit-Eligible Patients from Participating Clinics can either be youth (ages 5-20) or adults (ages 21+) and must be recipients of Medicaid, eligible for the MO Medicaid benefit (i.e., Medicaid recipients with obesity), and have been seen at participating FQHC clinics.\n\nExclusion Criteria - Provider Trainees:\n\n* Not at a participating clinic\n* PCPs who do not have the ability to refer to IBT or MNT\n* Resident Doctors\n* A doctor specializing in reproductive health (or related fields)\n\nExclusion Criteria - Benefit-Eligible Patients from Participating Clinics:\n\n* Patients without obesity\n* Patients not on Medicaid\n* Youth under the age of 5\n* Not a patient at a participating clinic","5 Years",{"count":127,"type":22},6200,[104],"This project will compare two training approaches for US Preventive Services Task Force recommended obesity care in Federally Qualified Health Centers (FQHC) across four aims. Aim 1 compares patient-level effectiveness \\[i.e., patient relative weight change and the proportion of patients who achieve clinically significant weight loss\\]. Aim 2 compares reach (patient treatment utilization). Aim 3 compares primary care provider (PCP) referrals to USPSTF-recommended care at 12 (adoption) and 24 months (maintenance) and short- and long-term changes in provider obesity care competencies . Aim 4 compares implementation and service costs.",[28,131,132,133,134],"Obesity Prevention","Obesity and Obesity-related Medical Conditions","Obesity and Overweight","Obesity",[136,137,138,139,134,140],"Training","Implementation","Intensive Behavioral Treatment","Family-based Behavioral Treatment","Obesity Care","2026-05-18",{"date":143,"type":34},"2026-05-20",{"date":145,"type":34},"2025-07-14",{"date":147,"type":22},"2028-12-15",{"name":149,"class":116},"Washington University School of Medicine",{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":4,"eligibilityCriteria":156,"healthyVolunteers":16,"sex":51,"minAge":18,"maxAge":157,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":162,"conditions":163,"keywords":165,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":42},"100611637","phase-1-a-phase-ibiia-study-to-evaluate-the-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-oral-ecnoglutide-tablets-in-chinese-participants-with-overweight-or-obesity-100611637","NCT07243171","A Phase Ib\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity","A Multicenter, Multiple-dose Escalation, Randomized, Double-blind, Placebo-controlled Phase Ib\u002FIIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral Ecnoglutide Tablets in Chinese Participants With Overweight or Obesity","Inclusion Criteria:\n\n1. At the time of informed consent, with BMI in the range of 24.0 to 35.0 kg\u002Fm2 (including the threshold), body weight \\>60.0 kg for male, and weight \\>50.0 kg for female;\n2. Self-declaration of body weight change \\\u003C5% within 3 months prior to informed consent ;\n\nExclusion Criteria:\n\n1. Diagnosis of overweight or obesity due to endocrine disorders , such as Cushing's syndrome;\n2. Diagnosis of other endocrine disorders with clinical significance, including but not limited to hyperthyroidism or hypothyroidism, thyroid nodules (imaging shows TI-RADS≥ class 3), thyroid cancer, or personal or family history of type 2 multiple endocrine tumor syndrome (MEN2), etc.\n3. Diagnosis of cardiovascular or cerebrovascular diseases with clinical significance within 6 months prior to screening, including but not limited to acute stroke, acute coronary syndrome, heart failure, arrhythmia, etc.\n4. Diagnosis of severe gastrointestinal diseases, including but not limited to inflammatory bowel disease, active ulcers, irritable bowel syndrome, celiac disease, dyspepsia, diabetic gastroparesis, diabetic diarrhea, clinical gastric emptying abnormalities (such as pyloric obstruction), etc.\n5. History of major gastrointestinal surgery (except cholecystectomy or appendectomy), or metabolic surgery, or plan to undergo major surgery during the study period;\n6. HbA1c ≥6.5% or fasting blood glucose ≥7.0 mmol\u002FL, or OGTT 2-hour blood glucose ≥11.1 mmol\u002FL, at screening;\n7. Clinical laboratory test results with clinical significance","65 Years",{"count":159,"type":22},84,[25,161],"PHASE2","The aim of the study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of oral ecnoglutide tablets in Chinese participants with overweight or obesity",[164,28],"Overweight and\u002For Obesity",[166,167,168,169,170],"ecnoglutide","glucagon-like peptide-1 (GLP-1)","obesity","overweight","weight management","2026-01-27",{"date":173,"type":34},"2026-01-28",{"date":175,"type":34},"2025-11-18",{"date":177,"type":22},"2026-11-22",{"name":179,"class":41},"Hangzhou Sciwind Biosciences Co., Ltd.",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":16,"sex":98,"minAge":18,"maxAge":188,"enrollmentInfo":189,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":192,"conditions":193,"keywords":199,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":42},"100613917","usability-study-of-gestational-and-postpartum-weight-management-program-100613917","NCT07272824","Usability Study of Gestational and Postpartum Weight Management Program","Usability Study of Gestational and 6 Months Postpartum Weight Management Program - Hope D","Hope-D_Use","Inclusion Criteria:\n\n* General pregnant women with prepregnancy BMI at least 30 kg\u002Fm2\n* Competence in using the digital care pathway and electronic maternity card\n\nExclusion Criteria:\n\n\\- Significant difficulty in cooperating (e.g. inadequate Finnish language skills)","50 Years",{"count":190,"type":22},30,"OBSERVATIONAL","The principal aim of this study is to evaluate the usability of the Hope-D gestational and 6 months postpartum weight management program. We will evaluate the usability, functionality, and acceptability of the developed Hope-D weight management program that includes digital pathway for weight management, general or individual weight management plan and individual or group coaching for weight management from pregnancy to 6 months postpartum.",[194,195,196,28,197,198],"Pregnancy","Postpartum","Obese Pregnant Women","Digital Intervention","Usability",[200,201,202,203,204,205],"Hope-D","digital pathway","Gestational weight management","Postpartum weight management","gestational weight management plan","coaching","2025-12-16",{"date":208,"type":34},"2025-12-23",{"date":210,"type":34},"2025-12-09",{"date":212,"type":22},"2026-01-31",{"name":214,"class":215},"Turku University Hospital","OTHER_GOV",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":98,"minAge":18,"maxAge":4,"enrollmentInfo":224,"targetDuration":226,"studyType":191,"phases":4,"briefSummary":227,"conditions":228,"keywords":231,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":42},"100583534","weight-loss-management-in-endometrial-cancer-survivors-100583534","NCT06877572","Weight Loss Management in Endometrial Cancer Survivors","Enacting Active Survivorship: Implementation of Weight Management Strategies in Endometrial Cancer Survivors","ECS Weight","Inclusion Criteria:\n\n* ≥18 years old\n* ECOG 0-2\n* BMI ≥ 30kg\u002Fm2\n* Completed surgical staging with no evidence of residual disease\n* Endometrioid endometrial adenocarcinoma, p53 wild type\n* Stage 1\n* Undergoing active surveillance +\u002F- brachytherapy\n\nExclusion Criteria:\n\n* Unable to participate in behavior weight loss\n* Stroke, heart attack, end stage liver disease, or end stage kidney disease during the last 6 months.\n* Currently on a GLP-1 agonist\n* Currently on insulin",{"count":225,"type":22},50,"1 Year","This study is being done to understand how oncologists can engage a multidisciplinary team to help endometrial cancer survivors with obesity to engage in a weight management program and potentially start a weight loss medication. Obesity often impacts the future health and longevity of early-stage endometrial cancer survivors more than their cancer diagnosis.\n\nPatients will be referred to the KUMC OB\u002FGyn weight management clinic to discuss weight management options.\n\n* If patients decide to use medications for weight loss, then the study will collect data from their chart that is recorded as part of routine monitoring for patients on weight loss medications.\n* If patients decide not to use any medications, the study will monitor physical exam and lab data collected as part of their routine medical care.\n\nThe study will also try to understand reasons why patients did or did not start using a weight loss medication.",[229,28,230],"Endometrial Cancer Survivors","Early Stage Endometrial Cancer",[232,229,28,233,234,235,236],"Endometrial Cancer","GLP-1 agonist","naltrexone\u002Fbupropion","orlistat","phentermine\u002Ftopiramate","2025-10-23",{"date":239,"type":34},"2025-10-27",{"date":241,"type":34},"2025-03-25",{"date":243,"type":22},"2030-10",{"name":245,"class":116},"University of Kansas Medical Center",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":16,"sex":51,"minAge":18,"maxAge":157,"enrollmentInfo":253,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":256,"conditions":257,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":42},"100599848","phase-1-a-study-of-yp05002-in-healthy-participants-100599848","NCT07089823","A Study of YP05002 in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of YP05002 in Healthy Participants","Inclusion Criteria:\n\n1. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.\n2. Healthy male and female participants aged 18-65 years (both inclusive).No restrictions on race.\n3. In good health as determined by the Investigator, with no clinically significant findings from medical\u002Fpsychiatric history, physical examination, 12-lead ECG, vital signs measurements, clinical laboratory evaluations.\n\nExclusion Criteria:\n\n1. Have evidence of any clinically significant active or chronic disease.\n2. Histories of using drug that affect drug absorption, distribution, metabolism, or excretion within 14 days or within 5-half-life prior to the first dose (whichever is longer); gastrointestinal disorders with impaired gastric emptying; or prolonged use of medications that directly modulate gastrointestinal motility.\n3. Had clinically relevant acute or chronic medical conditions or diseases that would pose a risk to participant's safety or interfere with the study assessments, as determined by the Investigator.\n4. Any malignancy (except basal cell carcinoma and squamous cell carcinoma of the skin) in the previous 5 years.\n5. Diagnosis of any type of pancreatitis.",{"count":254,"type":22},76,[25],"This is a phase I, randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, efficacy, food effect of YP05002 Tablets in healthy participants",[28],"2025-07-31",{"date":260,"type":34},"2025-08-06",{"date":262,"type":22},"2025-08-19",{"date":264,"type":22},"2026-06-30",{"name":266,"class":41},"Yaopharma Co., Ltd.",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":16,"sex":98,"minAge":275,"maxAge":276,"enrollmentInfo":277,"targetDuration":4,"studyType":23,"phases":279,"briefSummary":280,"conditions":281,"keywords":288,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":297,"locationsCount":42},"100569196","how-a-single-workout-affects-gut-bugs-in-women-with-different-fitness-levels-and-body-types-100569196","NCT06691100","How a Single Workout Affects Gut Bugs in Women With Different Fitness Levels and Body Types","The Acute Effects of an Endurance Exercise Bout the Gut Microbiome and Gut-derived Metabolome in Women's Distinct Fitness and Body Mass Indexes","FITGut-W","Inclusion Criteria:\n\n* Biological sex: female\n* BMI 19 to 24.99 kg\u002Fm2 or BMI 30-40 kg\u002Fm2\n* Exercisers: Exercise at least 4 times per week for 60 minutes (a total of 240 minutes per week) on a programmed exercise training either on endurance sports (e.g., running, cycling, triathlon), strength (e.g., powerlifting), or team sports (e.g., rugby, football, soccer)\n* Non-Exercisers: Sedentary individuals who have not reached the PA guidelines (150 minutes of moderate-intensity physical activity a week, 75 minutes of vigorous-intensity physical activity, or an equivalent combination of moderate and vigorous-intensity physical activity).\n\nExclusion Criteria:\n\n* Biological sex: male\n* BMI \\\u003C 19 kg\u002Fm2 or \\> 40 kg\u002Fm2\n* Currently pregnant, \\\u003C 2 years postpartum, lactating\n* Currently taking any herbal, fiber, or prebiotic supplement\n* Current or 1-month before the study, taking oral or vaginal antibiotics\n* Diagnosed with any gastrointestinal, endocrine, digestive, cancer, or cardiovascular disease.","21 Years","40 Years",{"count":278,"type":22},40,[104],"This study aims to elucidate the differences in the gut microbiome functional activity and metabolome in adult premenopausal women with distinctive fitness levels and BMIs (with obesity, w\u002Fo obesity). The specific aims are as follows:\n\n* Aim 1: To examine the effects of acute aerobic exercise at 60-70% heart rate reserve (HRRmax) for 30 minutes bout on changes in the abundance of SCFA-producing bacteria and their functional downstream metabolic activity.\n* Aim 2: To examine the effects of acute aerobic exercise at 60-70% HRRmax 30-minute bout on changes in GM-released SCFA concentrations in stool and plasmatic metabolome.",[28,134,282,283,284,285,286,287],"Exercise","Women","Gut Microbiome","Metabolome","Health","Gut Microbiota",[287,289,282,28,134],"Womens Health","2025-07-22",{"date":292,"type":34},"2025-07-24",{"date":294,"type":34},"2024-10-16",{"date":296,"type":22},"2027-10-16",{"name":298,"class":116},"George Washington University",{"id":300,"slug":301,"hasResults":11,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":306,"enrollmentInfo":307,"targetDuration":4,"studyType":23,"phases":308,"briefSummary":310,"conditions":311,"keywords":315,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":338,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":89},"100578274","phase-4-metabolic-and-behavioural-effects-of-contrave-as-potential-mechanisms-of-weight-loss-in-adults-with-obesity-100578274","NCT06809166","Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity","Identifying the Short-Term Neurobiological, Metabolic and Behavioural Effects of CONTRAVE as Potential Mechanisms of Weight Loss in Adults With Obesity: A Randomized, Double-Blind, Placebo-Controlled Pilot Trial","Inclusion Criteria:\n\n1. Participants who are able to provide written informed consent prior to the initiation of any protocol-required procedures\n2. Have been referred to the LEAF clinic by their physician or have self-referred to the LEAF clinic for weight loss, and have been deemed appropriate for weight loss treatment offered by the LEAF clinic (i.e., these criteria are at the discretion of the clinical team at the LEAF clinic, outlined below in the exclusion criteria section).\n3. Adults: aged 18-64 years of age (gender and sex will be noted; recruitment is all-gender inclusive).\n4. Have a BMI\\>30.\n5. Have normal or corrected vision as some of the study aspects will involve viewing\u002Fresponding to visual stimuli.\n6. Understand and speak English (as instructions for study criteria will be provided in English).\n7. Able to participate in the study protocol as described, e.g. have a means of getting to the laboratories and no major mobility issues to the extent that protocols cannot be followed (details below).\n8. Access to a secure internet connection (for virtual appointments with members of the LEAF clinic).\n\nExclusion Criteria:\n\n1. Reporting severe depression or reporting significant suicidal ideation, or history of bipolar disorder or psychosis (i.e., major psychiatric condition; this will be ascertained during the screening carried out by research personnel, in keeping with our standard protocols in Dr. Jaworska's laboratory).\\*\\*\\*\n2. Current use of antidepressants, thyroid medication, or any medication that could affect appetite, or seizure threshold (e.g.., bupropion, tamoxifen, thioridazine).\n3. Uncontrolled hypertension.\n4. History of cardiac defects or symptoms suggestive of any cardiac condition (not including coronary artery disease).\n5. Presence of diabetes.\n6. Current or past history of addictions or substance use disorder, including undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs.\n7. History of eating disorder (including Binge Eating Disorder, Bulimia Nervosa or Anorexia Nervosa).\n8. History of glaucoma.\n9. Personal or family history of seizure disorders.\n10. Currently taking MAO inhibitors (within 14 days), pressor agents, coumadin, anticonvulsants, or phenylbutazone, or other bupropion-containing products (such as Wellbutrin, Wellbutrin SR, Wellbutrin XL, Aplenzin or Zyban), or CYP2B6 inhibitors (e.g. ticlopidine or clopidogrel).\n11. History of thyroid disease, chronic liver, or renal disease.\n12. Chronic use of opioid, opiate agonist (Methadone) or partial agonists (Buprenorphine).\n13. Currently pregnant or planning to become pregnant during the intervention or currently nursing. Pregnancy urine test will be conducted during the in-person screening session in the laboratory.\\*\\*\\*\n14. No known allergy to any of the ingredients in CONTRAVE® (e.g. lactose).\n15. Hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption.\n16. Current use of obesity medications such as liraglutide or semaglutide or orlistat.\n17. Current use of medication indicated in patient living with ADHD (e.g., Vivanse\u002FConcerta) which are known to have metabolic impacts.\n\n    There are several additional exclusionary criteria, established by research personnel in Dr. Jaworska's laboratory (i.e., not part of LEAF intake) that preclude participation in the brain imaging\u002Fmagnetic resonance imaging (MRI) and EEG, these include:\n18. Severe claustrophobia.\n19. Inability to lie still in the scanner for approximately 30min.\n20. Metal in the body that cannot be removed and might pose a safety risk to the participant.\n21. History of concussion (loss of consciousness for \\>5-min).\n22. Major neurological illness, such as, epilepsy, stroke, tumours (as this would interfere with the interpretation of the MRI data).\n23. Obesity to the extent that the participant cannot fit into the scanner. This will be established by ensuring that the individual can fit into the mock scanner at the Brain Imaging Centre (BIC) of The Royal. If a person cannot fit into the mock scanner, it is unlikely that the person can fit into the real scanner.\n24. Testing positive for illicit drugs and cannabis (this will be established using a drug test that will be administered in the Clinical EEG \\& Neuroimaging laboratory at the Institute of Mental Health Research \\[IMHR\\]). Participants who are cannabis users will be invited to participate in the study so long as they can abstain from cannabis use for approximately 2weeks prior to the baseline session and approximately 2weeks before final assessment. Ideally, participants would also abstain from cannabis use during treatment, but, this will not be tested\u002Fenforced.\n25. Ability to abstain from nicotine\u002Ftobacco and caffeine for 3h prior to the baseline testing\u002FEEG recordings, as both substances influence EEG activity.\n\n    NOTE: If a participant cannot participate in the MRI aspect of the study (i.e., due to the above exclusion criteria), they will still be able to participate in the research study (apart from the MRI component). All MRI\u002FEEG exclusion criteria will be established during the screening\u002Fclinical interview carried out by trained research staff from Dr. Jaworska's laboratory (details below).\n\n    One final exclusion criterion is as follows:\n26. Unable to tolerate the test dose of CONTRAVE® (details below). Such individuals would not participate in further elements of the research, but, would continue with their treatment through the LEAF clinic (as determined by the LEAF clinic, per their clinical management program).","64 Years",{"count":278,"type":22},[309],"PHASE4","Obesity is a common chronic disease linked with increased risk for other illnesses and earlier death. Our team and others have shown that many bodily and psychological changes occur when individuals are on calorie-restricted diets. These changes might undermine dietary adherence and help to explain the relatively poor long-term efficacy of diets. These include increased appetite, increased food 'value' and 'wanting' that leads to overconsumption. Other factors include more sensitive sensory cues (e.g., smelling), higher food liking and craving, and a drop in resting energy expenditure (REE). REE has been shown to predict weight regain.\n\nThe standard care for obesity may include the use of the weight-loss drug CONTRAVE®. The Federal Drug Agency (FDA) and Health Canada have approved this drug for weight management and obesity treatment.\n\nAlthough CONTRAVE® was designed to reduce appetite, food-related impulsivity and cravings, its mechanisms of action are unclear. In other words, the effects of CONTRAVE® on REE, executive function, and brain changes remain unknown in humans. A better understanding of how this drug works on the brain and body could lead to improvements in obesity management in the future.\n\nAs such, the goal of this research is to study the effects of 4 weeks of CONTRAVE® (+ diet program) vs. control (placebo pill + diet program) on mood, body composition changes, biological\u002Fmetabolic measures, and brain measures.\n\nAdults aged 18-64 with obesity will be randomized to one of two groups: diet + CONTRAVE® (CONTRAVE®, 20 participants) or diet + Placebo (Placebo, 20 participants). Both groups will be assigned the same study procedures for the entire study duration. The only difference is that Group 1 will receive CONTRAVE® while Group 2 will receive a placebo (non-medical) pill.\n\nThe study design and intervention is as follows:\n\nParticipants who meet all the telephone screening criteria will be invited to the Clinical EEG \\& Neuroimaging Laboratory at The Royal's IMHR for an in-person screening and test-dose session. Participants who are cleared by the study physician, Dr. Pierre Blier, during the in-person screening will be enrolled in the 4-weeks trial.\n\nAfter the in-person screening visit, participants will attend two baseline testing visits (before starting the medication + diet program). The first will occur at the Behavioural and Metabolic Research Unit at the University of Ottawa. During this in-person visit, measures of body composition, resting energy expenditure, appetite, food craving, impulsivity, eating behaviours, taste and odour sensitivity, energy intake, and food preference will be collected.\n\nThe second baseline visit (within a week of the first one) will occur at The Royal\u002FIMHR. During this visit, participants will be asked to complete questionnaires. They will undergo an EEG recording while resting and performing computer tasks. They will also get a brain imaging scan, during which they are asked to rest and complete a computer task.\n\nBoth testing sessions (University of Ottawa and Royal Ottawa testing sessions) will be repeated after four weeks of treatment. The section below provides further description and timing of these visits.\n\nAs part of the treatment, you will receive an individualized dietary intervention with appropriate energy restriction from a registered dietitian at Dr. Judy Shiau's LEAF weight management clinic (called the 4-week BUDS program). The program involves weekly touch points with a registered dietitian and meal planning\u002Fcoaching. The diet intervention will commence the same week as the start of the placebo\u002FCONTRAVE®.\n\nDuring the 4-week intervention, participants will be asked to complete online questionnaires at various times.",[134,312,28,313,314],"Weight Loss","Dietary Intervention","Obesity\u002FTherapy",[316,317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337],"contrave","EEG","MRI","weight loss","appetitive behaviour","executive functioning","mood and weight loss","mood","body composition","symptoms of anxiety","symptoms of depression","energy expenditure","appetite","energy intake","food reward","reward processing","motivation","effort expenditure","delay discounting","brain activation","event related potentials","brain electrical activity","2025-07-21",{"date":292,"type":34},{"date":341,"type":34},"2024-07-04",{"date":343,"type":22},"2026-07-31",{"name":345,"class":116},"The Royal's Institute of Mental Health Research",{"id":347,"slug":348,"hasResults":11,"nctId":349,"briefTitle":350,"officialTitle":351,"acronym":352,"eligibilityCriteria":353,"healthyVolunteers":11,"sex":51,"minAge":354,"maxAge":355,"enrollmentInfo":356,"targetDuration":4,"studyType":191,"phases":4,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":42},"100590436","mitigation-of-cardiovascular-disease-risks-in-children-with-extreme-obesity-100590436","NCT06967389","Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity","Mitigation of Cardiovascular Disease Risks in Children With Extreme Obesity (MODERN)","MODERN","Inclusion Criteria:\n\n* Patient seen at University of Kentucky Pediatric High BMI Clinic\n* Diagnosis of Obesity Class 2 or 3\n* Meeting the clinical criteria for the medical intervention with semaglutide for weight loss\n\nExclusion Criteria:\n\n* Any current prescribed anti-obesity medications (AOM) such as Orlistat, Phentermine, Qsymia (Phentermine\u002FTopiramate), Liraglutide, Semaglutide, and Setmelanotide\n* Any current prescribed anti-hypertensive medications\n* Any specific end-organ acute concerns (kidney disease, liver disease, congenital disease).\n* Any active infections at enrollment.\n* Any systemic steroid use longer than 3 month use or within the last month before enrollment (not including inhaled, ophthalmic, intranasal, and topical).\n* Any limitations that would make exercise testing not possible.\n* Any congenital abnormality or genetic syndrome known to be associated with obesity\n* Pregnancy\n* Inability to receive an MRI\n* Personal or family history of medullary thyroid carcinoma (per product insert)\n* Patients with Multiple Endocrine Neoplasia syndrome type 2 (per product insert)","12 Years","17 Years",{"count":225,"type":22},"The goal of this clinical trial is to learn if the drug semaglutide changes markers of disease risk as it relates to weight in children ages 12-15 years old who are obese (class 2 or 3). The main questions it aims to answer are:\n\n* How do the rate of weight loss, body mass index (BMI), body composition, heart structure and function, and exercise ability interact with one another in the study population at enrollment?\n* How do risk markers of disease change over the study in the study participants who are given semaglutides to help with weight loss?\n* Are there differences in the above factors between males and females and are there key factors to help improve the outcomes?\n\nParticipants will be given semaglutide for this study. During the course of the study, participants will:\n\n* have two cardiac MRI scans OR two cardiac echocardiograms (one before starting semaglutide and one around 12 months after taking the drug)\n* have body composition and fitness levels assessed twice (before semaglutide and around 12 months after taking it) and have urine specific gravity (USG) measured\n* have extra blood drawn when labs their doctor orders are already being drawn (once at the beginning of the study, once around 6 months after enrollment, and once at the end of the study)\n* have follow up visits with the study doctor\n* be asked to take a pregnancy test if they are female and have started menstruation",[133,359,28,312,360],"Obese Adolescents","Cardiovascular Disease Risk Factor",[362,363,364,168,169,365,170,319],"semaglutide","Wegovy","Ozempic","adolescent","2025-07-01",{"date":368,"type":34},"2025-07-04",{"date":370,"type":34},"2025-06-12",{"date":372,"type":22},"2027-07",{"name":374,"class":116},"John Bauer",{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":23,"phases":384,"briefSummary":385,"conditions":386,"keywords":389,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":404,"locationsCount":406},"100480315","a-self-management-based-survivorship-intervention-for-chinese-cancer-survivors-100480315","NCT05534386","A Self-management Based Survivorship Intervention for Chinese Cancer Survivors","How to Prevent Lost in Transition? - Adaptive Randomised Controlled Trial of a Self-management Based Survivorship Intervention for Chinese Cancer Survivors","Inclusion Criteria:\n\n* Cantonese- or Mandarin-speaking Chinese patients diagnosed curable cancer\n* have completed primary and adjuvant treatment within the past six months\n\nExclusion Criteria:\n\n* Patients diagnosed with metastatic cancer",{"count":383,"type":22},486,[104],"This study, using a sequential multiple assessment randomized controlled trial (SMART) approach, will evaluate a cancer survivorship care intervention on physical symptom distress, weight management, self-efficacy in managing cancer and health-related quality of life among Chinese patients recently completed curative cancer treatment.",[387,28,388],"Physical Symptom Distress","Neoplasms",[390,391,392,393,394,395,396],"Physical symptom distress","Weight management","Self-efficacy in managing cancer","Health-related quality of life","Survivorship intervention","Sequential multiple assessment randomized controlled trial","psychooncology","2025-05-08",{"date":399,"type":34},"2025-05-13",{"date":401,"type":34},"2023-04-12",{"date":403,"type":22},"2026-12-31",{"name":405,"class":116},"The University of Hong Kong",7,{"id":408,"slug":409,"hasResults":11,"nctId":410,"briefTitle":411,"officialTitle":412,"acronym":4,"eligibilityCriteria":413,"healthyVolunteers":11,"sex":98,"minAge":18,"maxAge":414,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":421,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":427,"leadSponsor":429,"locationsCount":42},"100585393","application-assisted-weight-management-in-endometrial-cancer-fertility-preservation-100585393","NCT06901778","Application-Assisted Weight Management in Endometrial Cancer Fertility Preservation","Adaptive Behavioral Intervention Application for Weight Control in Obese\u002FOverweight Endometrial Cancer Patients in Fertility Preservation:A Randomized Clinical Trial","Inclusion Criteria:\n\n* BMI ≥ 25 kg\u002Fm²\n* Histologically confirmed endometrial carcinoma via diagnostic curettage, hysteroscopic endometrial biopsy, or needle biopsy\n* Clinical FIGO 2009 stage IA disease: No evidence of extrauterine metastasis or myometrial invasion on imaging (MRI\u002FCT)\n* ECOG \\\u003C 2\n* Active desire to preserve fertility\n* Fertility-preserving treatment\n* Willingness to participate and signed informed consent\n\nExclusion Criteria:\n\n* High-grade or p53-mutated (p53mut) endometrial cancer\n* Currently using weight-loss medications\n* Pregnant or breastfeeding\n* Presence of communication barriers that prevent understanding and participation in the informed consent process\n* Participation in other weight-loss programs\n* Inability to safely engage in unsupervised physical activities\n* Undergoing anticoagulant therapy that may affect body composition, weight, or energy expenditure\n* Severe comorbidities: urinary system stones, history of renal failure or severe renal insufficiency, familial dyslipidemia, severe liver disease, chronic metabolic acidosis, history of pancreatitis, severe diabetes, active gallbladder disease, fat malabsorption, severe cardiovascular and cerebrovascular diseases\n* Presence of unstable medical conditions: uncontrolled hypertension, diabetes, unstable angina, transient ischemic attack, other cancers currently under treatment, Crohn's disease","60 Years",{"count":416,"type":22},106,[104],"This study is a single-center, prospective, randomized controlled trial targeting endometrial cancer (EC) patients undergoing fertility-sparing treatment at Peking University People's Hospital from March 2025 to March 2027. The aim is to evaluate the efficacy of an intelligent mobile application (APP) based on the Adaptive Behavioral Intervention (ABI) framework in weight management for obese or overweight endometrial cancer patients receiving fertility preservation therapy. Additionally, the study seeks to explore its potential advantages in improving body mass index (BMI), tumor regression, and glucose and lipid metabolism profiles.",[232,420,28],"Mobile Applications",[422,420,312],"Endometrial Neoplasms","2025-03-31",{"date":425,"type":34},"2025-04-03",{"date":423,"type":22},{"date":428,"type":22},"2027-03-31",{"name":430,"class":116},"Peking University People's Hospital",{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":157,"enrollmentInfo":438,"targetDuration":4,"studyType":23,"phases":440,"briefSummary":441,"conditions":442,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":4},"100559572","phase-2-a-study-of-hrs9531-injection-in-obese-subjects-with-obstructive-sleep-apnea-100559572","NCT06565871","A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea","A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea (OSA)","Inclusion Criteria:\n\n1. Male or female subjects, age 18-65(both inclusive) at the time of signing informed consent.\n2. At screening visit, BMI 24-42kg\u002Fm2(both inclusive)\n3. Self-reported Diet and exercise control for at least 3 months before screening visit, and less than 5 kg self-reported change within the last 3 months.\n4. At screening visit, AHI ≥15 and Obstructive Sleep Apnea on PSG\n\nExclusion Criteria:\n\n1. Endocrine disorders that may significantly affect body weight, or obesity or hereditary obesity syndrome due to a single gene mutation;\n2. Diabetes (except gestational diabetes)\n3. There are diseases that may require systemic glucocorticoid therapy during the study period\n4. Any previous or planned surgery for sleep apnea or major ear, nose or throat surgery, including tonsillectomy and adenoidectomy that still may affect breathing at time of screening Visit .Inclusion of a participant with more minor ear, nose or throat surgery (for example, deviated septum) will be at the investigator's discretion.\n5. Previous or known history or family history of medullary thyroid carcinoma (MTC) or multiple endocrine adenomatosis type 2 (MEN2)\n6. In or suspected of depression, bipolar disorder, suicidal tendencies, schizophrenia or other more serious mental illness;\n7. Use of drugs or treatments that may lead to significant weight gain or loss within 3 months, use of stimulants and hypnotics, mirtazapine, opioids, trazodone within 3 months;\n8. Patients with a history of blood donation or blood loss ≥400 ml within 3 months prior to screening, or receiving blood transfusions within 3 months\n9. During the screening or before randomization ,laboratory examination meets the following conditions:\n\nFasting blood glucose ≥7.0 mmol\u002FL, or HbA1c ≥6.5%; Hemoglobin \\\u003C100 g\u002FL; Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥3× upper limit of normal range (ULN), total bilirubin (TBIL) ≥2.0×ULN; Estimated glomerular filtration rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73 m2 (calculated based on serum creatinine using CKD-EPI formula); Fasting triglyceride (TG) \\>5.64 mmol\u002FL (500 mg\u002Fdl); calcitonin ≥50 ng\u002FL; Blood amylase or lipase ≥3×ULN; Thyroid stimulating hormone (TSH) \\\u003C0.4 or \\>6.0 mIU\u002FL; Abnormalities in other laboratory tests that the investigator determines may affect the assessment of efficacy or safety;\n\n10、The 12-lead electrocardiogram (ECG) examination revealed clinically significant abnormalities that the investigators determined may affect the safety of the subject and QTcF\\>450 ms; 11、Poor blood pressure control: systolic blood pressure ≥160 mmHg, or diastolic blood pressure ≥110 mmHg, or diastolic blood pressure ≥100mmHg and deemed unsuitable for study by investigator; 12、Clinically relevant medical behavior or psychiatric disorder (other than OSA), that is associated with insomnia or excessive sleepiness in the past and at the time of screening; 13、Severe infection, severe trauma, or major or large surgery within 1 month prior to screening 14、Malignancy of any organ system within 5 years, regardless of evidence of local recurrence or metastasis; 15、A known or suspected history of alcohol and\u002For drug abuse; 16、The presence of a serious hematological disorder; 17、Surgery is planned during the trial (except for minor surgery that the investigators believe will not affect the trial) 18、Mentally incapacitated or speech-impaired subjects are unable to fully understand or participate in the test process; 19、In the investigator's judgment, there are circumstances (medical, psychological, social, or geographical factors, etc.) that affect subject safety or any other conditions that interfere with the evaluation of test results.",{"count":439,"type":22},108,[161],"The purpose of this study is to evaluate the effect and safety of HRS9531 Injection in Obese Subjects with Obstructive Sleep Apnea",[28],"2024-08-20",{"date":445,"type":34},"2024-08-22",{"date":447,"type":22},"2024-08",{"date":449,"type":22},"2025-12",{"name":40,"class":41},{"id":452,"slug":453,"hasResults":11,"nctId":454,"briefTitle":455,"officialTitle":455,"acronym":456,"eligibilityCriteria":457,"healthyVolunteers":16,"sex":51,"minAge":18,"maxAge":458,"enrollmentInfo":459,"targetDuration":4,"studyType":23,"phases":461,"briefSummary":462,"conditions":463,"keywords":476,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":4},"100552680","m4c-nutraceutical-intervention-human-health-effects-pilot-100552680","NCT06476236","M4C Nutraceutical Intervention Human Health Effects Pilot","M4C Pilot","Inclusion Criteria:\n\n* Healthy adults\n\nExclusion Criteria:\n\n* amputation\n* blood clotting disorder\n* metal implants or implanted electrical device(s)\n* known acute or chronic illness; gastrointestinal, cardiac, pulmonary, liver, or kidney abnormalities, uncontrolled hypertension\n* inability to fast i.e. low blood sugar\n* pregnant or may be pregnant during the course of the study\n* amino acid metabolizing disorder i.e. phenylketonuria\n* severe edema\n* did not pass screening criteria as determined by MRI facility\n* allergies\u002Fintolerance to any nutraceutical ingredients: amino acids, vitamins, minerals, tapioca starch, sunflower lecithin, stevia, limes or fatty acids like docosahexaenoic acid","80 Years",{"count":460,"type":22},20,[104],"This 3 month pilot study will be an unblinded, convenience sampling, nutraceutical intervention trial. Twenty fasted subjects will undergo a baseline health assessment via a questionnaire, baseline clinical chemistries, blood lipids, dexa and impedence testing (to identify bone mineral density and body muscle\u002Ffat\u002Fwater composition), and metabolite\u002Fnovel biomarker testing through whole capillary blood, saliva, and urine collections. Assessments will be repeated every month (3 times after initial assessment) to cover a 3 month period. All measurements from each visit will be compared with baseline using paired t-tests or Chi square testing depending on variable. Power analyses are not included due to the pilot nature of the study. This pilot study will provide the necessary variability estimates for future trials.",[464,465,466,28,467,468,469,470,471,472,473,474,134,475],"General Health and Wellness","Energy and Vitality","Cognitive Function and Mental Health","Digestive Health","Exercise Tolerance","Cardiovascular Health","Bone and Joint Health","Skin, Hair, and Nail Health","Immune Support","Sports Performance and Recovery","Sleep and Relaxation","Anti Inflammatory",[464,465,466,28,467,468,469,470,471,472,473,477,134,478],"Sleep and relaxation","anti inflammatory","2024-06-24",{"date":481,"type":34},"2024-06-26",{"date":483,"type":22},"2024-06-17",{"date":485,"type":22},"2025-06-17",{"name":487,"class":116},"Concordia University Wisconsin"]